HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $130 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and maintained a price target of $130. This endorsement reflects the firm's confidence in the company's performance and potential in the market.